New therapeutic approaches in inflammatory bowel disease

Netherlands Journal of Medicine

Volumn 50, Issue 2, 1997, Pages

  Hodgson, H J F ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Anti TNF ; Crohn's disease; Inflammatory bowel disease; Interleukin; Therapy; Ulcerative colitis

Indexed keywords

ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; CORTICOSTEROID;

CONFERENCE PAPER; CROHN DISEASE; DRUG EFFECT; DRUG EFFICACY; DRUG METABOLISM; ENTERITIS; HUMAN; INTESTINE MUCOSA; ULCERATIVE COLITIS;

ANTIBODIES, MONOCLONAL; HUMANS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; RECEPTORS, CYTOKINE;

EID: 0031050472     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-2977(96)00066-6     Document Type: Conference Paper

References (22)

1. Turunen U, Farkiia M, Hakala K, et al. A double-blind, placebo controlled six month ciprofloxacin treatment improves prognosis in ulcerative colitis. Gastroenterology 1994;106:A786.
2. Rutgeerts P, Hiele M, Geboes K, et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 1995;108(6):1617-1621.
3. Playford RJ, Hanby AM, Patel K, Calam J. Influence of inflammatory bowel disease on the distribution and concentration of pancreatic secretory trypsin inhibitor within the colon. Am J Pathol 1995;146(2):310-316.
4. Procaccino F, Reinshagen M, Hoffmann P, et al. Protective effect of epidermal growth factor in an experimental model of colitis in rats. Gastroenterology 1994;107(1):12-17.
5. Poulson R, Chinery R, Sarraf C, et al. Trefoil peptide gene expression in small intestinal Crohn's disease and dietary adaptation. J Clin Gastroenterol 1993;17(suppl 1):S78-S91.
6. Pooley N, Ghosh L, Sharon P. Upregulation of E-selectin and intercellular adhesion molecule-1 differs between Crohn's disease and ulcerative colitis. Dig Dis Sci 1995;40(1):219-225.
7. Podolsky DK, Lobb R, King N, et al. Attenuation of colitis in the cotton-top tamarin by anti-alpha 4 integrin monoclonal antibody. J Clin Invest 1993;92(1):372-380.
8. Mori A, Suko M, Nishizaki Y, et al. IL-5 production by CD4+ T cells of asthmatic patients is suppressed by glucocorticoids and the immunosuppressants FK506 and cyclosporin A. Int Immunol 1995;7(3):449-457.
9. Rachmilewitz D, Eliakim R, Simon P, Ligumsky M, Karmeli F. Cytokines and platelet-activating factor in human inflamed colonic mucosa. Agents Actions 1992;spec no:C32-C36.
10. Isaaca KL, Sartor RB, Haskill S. Cytokine messenger RNA profiles in inflammatory bowel disease mucosa. Gastroenterology 1992;103:1587-1595.
11. Buchwald S, Emmrich J, Seyfarth M, Emmrich F. Follow-up study of the development of autoantibodies in patients with chronic inflammatory bowel disease under anti-CD4 therapy. Immun Infekt 1993;21(suppl 10):34-35.
12. van Dullemen HM, van Deventer SJ, Hommes DW, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995;109(1):129-135.
13. Wardle TD. Interleukin 10 inhibits inflammatory mediator production in ulcerative colitis. Gut 1994;35:S48.
14. Cominelli F, Nast CC, Duchini A, Lee M. Recombinant interleukin-1 receptor antagonist blocks the proinflammatory activity of endogenous interleukin-1 in rabbit immune colitis. Gastroenterology 1992;103(1):65-71.
15. Mansfield JC, Holden H, Tarlow JK, et al. Novel genetic association between ulcerative colitis and the anti-inflammatory cytokine interleukin-1 receptor antagonist. Gastroenterology 1994;106(3):637-642.
16. Roediger WE, Millard S. Selective inhibition of fatty acid oxidation in colonocytes by ibuprofen: a cause of colitis? Gut 1995;36(1):55-59.
17. Vernia P, Cittadini M, Caprilli R, Torsoli A. Topical treatment of refractory distal ulcerative colitis with 5-ASA and sodium butyrate. Dig Dis Sci 1995;40(2):305-307.
18. Greenfield SM, Punchard NA, Teare JP, Thompson RP. The mode of action of the aminosalicylates in inflammatory bowel disease. Aliment Pharmacol Ther 1993;7(4):369-383.
19. Ikehata A, Hiwatashi N, Kinouchi Y, Ito K, Yamazaki H, Toyota T. 5-Aminosalicylic acid inhibits leukotriene B4 omega-hydroxylase activity in human polymorphonuclear leukocytes. Prostagl Leukotr Essent Fatty Acids 1994;50(6):317-320.
20. Caesar I, Gross V, Roth M, et al. Treatment of active Crohn's ileocolitis with oral pH-modified budesonide. Germany Budesonide Study Group. Z Gastroenterol 1995;33(5):247-250.
21. Van Ierssel AJ, Van der Sluys-Veer A, Verspaget HW, Griffioen G, Van Hogezand RA, Lamers CB. Budesonide and prednisolone suppress peripheral blood natural killer cells in Crohn's disease. Aliment Pharmacol Ther 1995;9(2):173-178.
22. Rutgeerts P, Lofberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994;331(13):842-845.